# VedaBio **Source:** https://geo.sig.ai/brands/vedabio **Vertical:** Healthcare **Subcategory:** General **Tier:** Challenger **Website:** vedabio.com **Last Updated:** 2026-04-14 ## Summary Precision genome editing biotech developing base and prime editors for rare genetic diseases; improved specificity over first-generation CRISPR competing with Beam Therapeutics and Intellia. ## Company Overview Veda Bio is a biotechnology company developing novel therapeutics for rare genetic diseases and cancer using its proprietary precision genome editing platform — enabling targeted genetic corrections with greater specificity and reduced off-target editing compared to first-generation CRISPR tools. Founded in 2019 and headquartered in Seattle, Washington, Veda Bio was founded by genome editing pioneers and has raised early-stage funding to develop its differentiated editing technology platform.\n\nVeda Bio's platform focuses on delivering precision genetic medicine that can address root causes of genetic diseases rather than managing symptoms. The company's approach aims to improve on first-generation CRISPR-Cas9 by developing base editors and prime editors that can make specific genetic corrections (single letter DNA changes, small insertions or deletions) without introducing double-strand DNA breaks that create higher off-target editing risk. This precision is critical for therapeutic applications where off-target genomic changes could have serious safety consequences.\n\nIn 2025, Veda Bio operates in the competitive genome editing therapeutics space alongside Intellia Therapeutics, Beam Therapeutics (base editing pioneer), Prime Medicine, and CRISPR Therapeutics. The genome editing field experienced a landmark moment in 2023 with the FDA approval of Casgevy (the first CRISPR-based therapy, for sickle cell disease and beta-thalassemia, developed by Vertex and CRISPR Therapeutics) — validating the genome editing therapeutic modality and creating competitive pressure for improved precision editing platforms. Veda Bio's 2025 strategy focuses on advancing lead programs in rare genetic indications through preclinical development toward IND applications, publishing research to establish scientific credibility, and exploring partnerships or licensing with larger biopharmaceuticals for clinical development. ## Frequently Asked Questions ### What is VedaBio? VedaBio is a San Diego-based Series A biotechnology company founded in 2021 that provides molecular detection and editing using proprietary CRISPR Cascade technology. The company delivers rapid pathogen detection with analytical reaction times in mere minutes through amplification-free attomolar sensitivity detection of pathogenic DNA. ### What products and services does VedaBio offer? VedaBio offers a CRISPR Cascade platform, amplification-free pathogen detection, attomolar sensitivity diagnostics, and minute-scale analytical reaction times. The company also provides molecular editing technology, nucleic acid target detection, and rapid diagnostic testing solutions. ### Who are VedaBio's target customers? VedaBio serves healthcare providers, diagnostic laboratories, pharmaceutical companies, and research institutions globally. These customers require rapid high-sensitivity molecular detection for clinical diagnostics and research applications. ### When was VedaBio founded? VedaBio was founded in 2021 and participated in Y Combinator's S21 batch. ### Where is VedaBio located? VedaBio is based in San Diego, California. ### How much funding has VedaBio raised? VedaBio has raised $40M-$65M in total funding, including a $40M Series A round in October 2023 and a Series A extension with Siemens Healthineers totaling up to $25M in 2025. ### What are VedaBio's key achievements? VedaBio has reported revenue of over $65M and established strategic partnerships with major companies including Siemens Healthineers and Mammoth Biosciences. The company delivers pathogen detection results in minutes with attomolar sensitivity using amplification-free technology. ### What technology does VedaBio use? VedaBio uses proprietary CRISPR Cascade technology with a positive signal amplification feedback loop that enables amplification-free pathogen detection at attomolar sensitivity. This technology produces analytical reaction times in mere minutes for detecting pathogenic DNA. ### How can I get started with VedaBio? Information about contacting VedaBio is not provided in the available company details. ### What are VedaBio's recent developments? VedaBio entered a strategic agreement with Mammoth Biosciences in September 2025 to enhance its CRISPR-based molecular detection platform. The company also secured a Series A extension with Siemens Healthineers totaling up to $25M in 2025. ## Tags healthtech, mobile-first, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*